Se connecter
Recherche
Intranet
Thème

Presentation

Founded in 1989, the Institute of Molecular and Cellular Pharmacology (IPMC) is a research center located in the exceptional Sophia Antipolis site, Europe’s leading technology park: 2,500 companies, 10,000 students and researchers, and the presence of France’s leading research institutions in the field of biological sciences.

The IPMC is a joint research unit between the French National Center for Scientific Research (CNRS), Université Côte d’Azur (UniCA), and the French National Institute of Health and Medical Research (Inserm). A global reference center for the study of ion transport, the Institute has gradually expanded its field of investigation. Its 22 teams conduct research ranging from molecules to organisms in topics as varied as pharmacology, physiology and functional genomics. This work aims to define the dysfunctions associated with numerous pathologies and is applied in the development and evaluation of new diagnostics and treatments for cancer, epilepsy, and metabolic, renal, neurovascular and neurodegenerative diseases.

Research teams benefit from a high-level technological environment in molecular and cellular biology, imaging, cytometry, biomolecule analysis, electrophysiology, functional genomics and integrative biology.

Indicateurs

0
Équipes de recherche
0
Chercheurs
0
Membres
0
Programmes Investissement d’Avenir
0
Réseaux Hospitalo-Universitaires
0
Brevets
0
Articles publiés
0
Projets scientifiques

Within a high-performance network

The IPMC is working to develop biology at the Nice-Sophia Antipolis site with:

– scientific organizations and foundations;
– industries, either directly or through competitiveness clusters, or by contributing to the creation of biotechnology start-ups.

Scientific excellence

IPMC researchers are working on new therapeutic targets associated with human diseases. Through their study of the major functions of living organisms, they are involved in numerous programs of excellence within the government’s Future Investment Programs (Programmes d’investissements d’avenir) :

Institutional oversight